ANI Pharmaceuticals logo
ANI Pharmaceuticals ANIP
$ 79.9 -0.55%

Quarterly report 2025-Q3
added 11-07-2025

report update icon

ANI Pharmaceuticals Financial Statements 2011-2026 | ANIP

Annual Financial Statements ANI Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.2 B 1.21 B 700 M 509 M 341 M 725 M 633 M 779 M 666 M 364 M 612 M 107 M 31.5 M 64 M

Shares

19.3 M 18 M 16.3 M 12.6 M 12 M 11.8 M 11.7 M 11.5 M 11.4 M 11.4 M 10.9 M 5.07 M 3.63 M 2.73 M

Historical Prices

61.9 67 43.1 40.4 28.5 62 53.7 67.2 60.5 32 56 22.2 8.34 23.4

Net Income

-18.5 M 18.8 M -47.9 M -42.6 M -22.5 M 6.09 M 15.5 M -1.08 M 3.93 M 15.4 M 28.7 M 301 K -27.7 M -51.6 M

Revenue

614 M 487 M 316 M 216 M 208 M 207 M 202 M 177 M 129 M 76.3 M 56 M 30.1 M 2.3 M 435 K

Cost of Revenue

250 M 182 M 139 M 101 M 87.2 M 63.2 M 73 M 79 M 48.8 M 12.7 M 11.5 M 9.97 M 9.17 M -

Gross Profit

- - - - - 143 M 129 M 97.8 M 79.8 M 63.6 M 44.5 M 20.1 M 2.3 M 385 K

Operating Income

584 K 47 M -35.3 M -39.8 M -16 M 16.4 M 35.4 M 28.3 M 20.1 M 32.7 M 20 M 898 K -42 K -

Interest Expense

-4.03 M -159 K 670 K -4.34 M -494 K -228 K -550 K 55 K -74 K 41 K 160 K 467 K 348 K 682 K

EBITDA

68.3 M 107 M 21.7 M 7.46 M 28.6 M 61 M 69.1 M 57.2 M 49.1 M 39.6 M 23.9 M 2.01 M -22.9 M -50.8 M

Operating Expenses

- - - - - 127 M 93.2 M 68.6 M 53.1 M 30.9 M 24.5 M 19.2 M 25.5 M 51.3 M

General and Administrative Expenses

250 M 162 M 124 M 84.3 M 65 M 55.8 M 44.1 M 31.6 M 27.8 M 21.2 M 17.9 M 16.4 M 8.23 M 6.98 M

All numbers in USD currency

Quarterly Income Statement ANI Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

20.1 M 19.8 M 19.6 M 19.4 M 19.3 M 19.1 M 18.9 M 17.7 M 16.4 M - 16.3 M 16.3 M 16.1 M - 12.1 M 12.1 M 12 M - 12 M 12 M 11.9 M - 11.9 M 11.9 M 11.7 M - 11.7 M 11.7 M 11.6 M - 11.6 M 11.5 M 11.5 M - 11.5 M 11.4 M 11.4 M - 11.4 M 11.3 M 11.3 M - 11.2 M 11.2 M 9.99 M - 9.48 M 1.15 M - - 22.9 M 20.2 M 116 M - 17.4 M 15.7 M 84.8 M

Net Income

26.6 M 8.55 M 15.7 M -24.2 M -2.29 M 18.2 M 9.94 M 6.24 M 1.44 M - -8.6 M -14.9 M -20.1 M - -4.45 M -14.1 M 86 K -3.64 M 434 K -12.3 M -7.01 M -4.84 M 3.9 M 6.58 M 449 K - 5.04 M 2.78 M 2.25 M - 4.72 M 2.68 M 1.15 M - 2.54 M 1.12 M 1.35 M - 4.56 M 3.57 M 4.37 M - 6.75 M -2.36 M 3.36 M - 1.19 M -4.58 M 260 K -3.99 M -377 K 35.4 K -10.3 M -6.65 M -12.7 M -15 M -17.3 M

Revenue

228 M 211 M 197 M 148 M 138 M 137 M 132 M 117 M 107 M - 83.8 M 73.9 M 64.5 M - 52.1 M 48.6 M 54.5 M 57.3 M 53 M 48.5 M 49.8 M 48 M 51.3 M 54.4 M 52.9 M 57.1 M 50.7 M 47.3 M 46.5 M 47.3 M 48.2 M 44.8 M 36.6 M 38.2 M 38.5 M 31.3 M 20.6 M 18 M 20 M 19.5 M 18.8 M 21 M 17.4 M 6.65 M 10.9 M - 7.84 M 6.15 M 5.56 M 1.97 M 5.04 M 5.19 M 114 K 114 K 183 K 81 K 57 K

Cost of Revenue

93.4 M 74.6 M 73 M 63.1 M 57.7 M 49.2 M 48.1 M 42.3 M 37.7 M - 32.9 M 35.3 M 34.3 M - 24.4 M 22.3 M 20 M - 20.1 M 20.7 M 21.8 M - 15 M 15.6 M 14.7 M - 15.6 M 16.6 M 20.7 M - 21.1 M 21.1 M 16.4 M - 16.7 M 11.8 M 3.41 M - 3.26 M 3.14 M 2.75 M - 3.06 M 2.12 M 2.62 M - 2.71 M 2.17 M 2.41 M - 2.32 M 2.12 M - - - - -

Operating Income

36.2 M 13.9 M 26.2 M -20.5 M 5.17 M 20.3 M 17.9 M 12.4 M 9.9 M - -5 M -12.9 M -19.2 M - -3.56 M -15.6 M 3.04 M 331 K 2.8 M -11.3 M -7.84 M -4.67 M 7.33 M 9.29 M 4.4 M 11.4 M 10.1 M 7.26 M 6.54 M 7.38 M 9.33 M 6.99 M 4.62 M 1.3 M 7.92 M 5.19 M 5.67 M 6.27 M 8.45 M 8.41 M 9.57 M 10.8 M 8.2 M -2.46 M 3.5 M - 810 K -3.78 M 403 K -3.64 M -207 K 586 K -6.93 M -8.34 M -13 M -13.1 M -16.4 M

Interest Expense

-853 K 1.74 M 198 K -2.54 M -88 K -32 K -39 K -53 K -34 K - 37 K 764 K -89 K - -1.07 M -67 K -515 K - -229 K -116 K 10 K - -33 K 46 K -130 K - 20 K -30 K -61 K - 95 K -19 K -18 K - -21 K -12 K 2 K - -28 K - 68 K - 82 K -39 K - - - 374 K 93 K - 81.2 K 501 K 124 K - 172 K 172 K 172 K

EBITDA

58.9 M 37.2 M 49.1 M -4.77 M 19.9 M 35 M 33.2 M 27.1 M 24.6 M - 9.17 M 851 K -4.64 M - 7.78 M -4.23 M 13.9 M 331 K 14.2 M -109 K 3.34 M -4.67 M 16.8 M 18.8 M 20.5 M 11.4 M 18.7 M 15.6 M 14.7 M 7.38 M 16.4 M 14.1 M 11.3 M 1.3 M 13.9 M 11.2 M 10.3 M 6.27 M 10.5 M 9.83 M 10.9 M 10.8 M 9.39 M -1.75 M 4.2 M - 1.19 M -3.63 M 548 K -3.64 M -63.4 K 727 K -6.9 M -8.34 M -13 M -13 M -16.4 M

General and Administrative Expenses

76.7 M 81.8 M 76.5 M 79.1 M 52.8 M 48 M 42 M 38.8 M 36.5 M - 30.1 M 32 M 28.8 M - 17.2 M 18.8 M 17.6 M - 15.7 M 21.2 M 13.7 M - 14.4 M 14.2 M 13.3 M - 11.8 M 9.96 M 8.96 M - 8.02 M 7.38 M 7.29 M - 6.93 M 7.63 M 5.9 M - 5.4 M 5.55 M 4.75 M - 4.06 M 5.43 M 3.7 M - 3.48 M 7.17 M 1.95 M 2.9 M 1.55 M 1.95 M 1.83 M 1.72 M 1.68 M 1.99 M 1.59 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ANI Pharmaceuticals ANIP
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ANI Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.48 -1.67 % $ 277 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.7 -0.34 % $ 5.99 B irlandaIrlanda
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 5.24 % $ 4.8 M chinaChina
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 2.66 -0.37 % $ 150 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.5 -2.1 % $ 8.42 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.96 0.56 % $ 27.2 B germanyGermany
Cabaletta Bio Cabaletta Bio
CABA
$ 2.48 1.64 % $ 2.9 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.75 2.05 % $ 157 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 220.07 -0.88 % $ 5 B danmarkDanmark
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 41.12 -0.46 % $ 4.24 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.23 2.9 % $ 1.44 B britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.29 -0.67 % $ 2.88 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.94 0.48 % $ 4.21 B schweizSchweiz
Champions Oncology Champions Oncology
CSBR
$ 6.54 -0.15 % $ 89.3 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.45 5.33 % $ 9.68 B israelIsrael
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.46 - $ 373 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.48 -0.28 % $ 4.47 B usaUSA